UBS Group
BCTXZ

UBS Group’s BriaCell Therapeutics Corp Warrant BCTXZ Stock Holding History

UBS Group’s Portfolio BCTXZ Stock Details BCTXZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,697
Closed -$658 – 11417
2026
Q1 		$658 Buy
4,697
+4,692
+93,840% +$787 ﹤0.01% 9797
2025
Q4 		$1 Sell
5
-61
-92% -$23 ﹤0.01% 10433
2025
Q3 		$22 Sell
66
-1,123
-94% -$372 ﹤0.01% 10126
2025
Q2 		$1.26K Buy
+1,189
New +$1.28K ﹤0.01% 9649

Other funds holding BCTXZ

HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

UBS Group's BCTXZ Position: Q2 2026 in Review

UBS Group sold out of BriaCell Therapeutics Corp Warrant (BCTXZ) in Q2 2026, closing a stake of 4,697 shares — an estimated $658 sold.

UBS Group first reported a position in BCTXZ in Q2 2025 and held it in 4 quarters. The position peaked at $1.26K in Q2 2025. 5 funds tracked by Wall St. Rank hold BCTXZ as of Q2 2026.

  • UBS Group reported no remaining BriaCell Therapeutics Corp Warrant position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 4,697 BriaCell Therapeutics Corp Warrant shares in Q2 2026, an estimated $658.
  • UBS Group first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2025 and held it in 4 quarters.
  • UBS Group's BriaCell Therapeutics Corp Warrant position peaked at $1.26K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.